News & Publications - Page 3 of 7

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019

  • KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting

  • KemPharm Provides Updates Regarding its Board of Directors

  • KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases

  • KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.

  • KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital

  • KemPharm Reports Second Quarter 2019 Results

  • KemPharm Reports First Quarter 2019 Results

  • KemPharm Completes KP415 Pre-NDA Meeting with FDA

  • KemPharm Provides Update on APADAZ® Formulary Adoption

  • KemPharm to Present at Upcoming Investor Conferences

  • KemPharm Reports Q4 and FY 2018 Results